Difficulties in diagnosing primary hyperaldosteronism

Primary hyperaldosteronism (PA) is a disorder with excessive secretion of aldosterone, uncontrolled of regulation of the renin-angiotensin system. Excess secretion of aldosterone leads to the development of hypertension, hypokalemia and specific damage to the cardiovascular system and kidneys. The prevalence of PA was previously underestimated, but at the moment, according to studies, it is the most common cause of secondary arterial hypertension. The most common causes of PA are adrenal adenoma and adrenal hyperplasia. The importance of timely diagnosis of PA lies not only in solving the problem of high blood pressure, but because of the extremely adverse effect of excess aldosterone on the cardiovascular system and kidneys, which can even lead to death. The aldosterone-to-renin ratio (ARR) has long been a selective test for PA screening, but the complexity of its interpretation, the lack of clear cut-off level, and the confusion of measurement units make it difficult to evaluate, which has led some researchers to look for new ways for PA screening. The distinction between idiopathic adrenal hyperplasia (IAH) and aldosterone-producing adenoma (APA) is important for choosing the appropriate treatment. Therefore, imaging exams such as computed tomography and invasive studies such as adrenal catheterization are required to identify the PA subtype. Depending on the subtype of PA, it is necessary to use the optimal treatment — surgical for APA or pharmacological for hypertension, using drugs such as mineralocorticoid receptor antagonists.

1. Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-916. doi:10.1210/jc.2015-4061.

2. Sinclair AM, Isles CG, Brown I, et al. Secondary hypertension in a blood pressure clinic. Arch Intern Med. 1987;147(7):1289-93.

3. Käyser SC, Dekkers T, Groenewoud HJ, et al. Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab. 2016;101(7):2826-35. doi:10.1210/jc.2016-1472.

4. Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies–a review of the current literature. Horm Metab Res. 2012;44(3):157-62. doi:10.1055/s-0031-1295438.

5. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89(3):1045-50. doi:10.1210/jc.2003-031337.

6. Monticone S, Burrello J, Tizzani D, et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol. 2017;69(14):1811-20. doi:10.1016/j.jacc.2017.01.052.

7. Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab. 2015;100(1):1-10. doi:10.1210/jc.2014-3663.

8. Loh KC, Koay ES, Khaw MC, et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab. 2000;85(8):2854-9. doi:10.1210/jcem.85.8.6752.

9. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293-300. doi:10.1016/j.jacc.2006.07.059.

10. Piaditis G, Markou A, Papanastasiou L, et al. Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension. Eur J Endocrinol. 2015;172(5):R191-R203. doi:10.1530/EJE-14-0537.

11. Jansen PM, Boomsma F, van den Meiracker AH, et al. Aldosterone-to-renin ratio as a screening test for primary aldosteronism–the Dutch ARRAT Study. Neth J Med. 2008;66(5):220-8.

12. Burrello J, Monticone S, Losano I, et al. Prevalence of Hypokalemia and Primary Aldosteronism in 5100 Patients Referred to a Tertiary Hypertension Unit. Hypertension. 2020;75(4):1025-33. doi:10.1161/HYPERTENSIONAHA.119.14063.

13. Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168(1):80-5. doi:10. 1001/archinternmed.2007.33.

14. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243-8. doi:10.1016/j.jacc.2005.01.015.

15. Mulatero P, Monticone S, Bertello C, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98(12):4826-33. doi:10.1210/jc.2013-2805.

16. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62(2):331-6. doi:10.1161/HYPERTENSIONAHA.113.01060.

17. Monticone S, D’Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41-50. doi:10.1016/S2213-8587(17)30319-4.

18. Stowasser M, Sharman J, Leano R, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab. 2005;90(9):5070-6. doi:10.1210/jc.2005-0681.

19. Iwakura Y, Morimoto R, Kudo M, et al. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J Clin Endocrinol Metab. 2014;99(5):1593-8. doi:10.1210/jc.2013-2180.

20. Wu VC, Chueh SJ, Chen L, et al. Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years. J Hypertens. 2017;35(8):1698-708. doi:10.1097/HJH.0000000000001361.

21. Stowasser M, Gordon RD, Gunasekera TG, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after ‘non-selective’ screening of hypertensive patients. J Hypertens. 2003;21(11):2149-57. doi:10.1097/00004872-200311000-00025.

22. Rossi GP, Cesari M, Cuspidi C, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. 2013; 62(1):62-9. Erratum in: Hypertension. 2014;64(6):e7. doi:10.1161/HYPERTENSIONAHA.113.01316.

23. Catena C, Colussi G, Lapenna R, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007;50(5):911-8. doi:10.1161/HYPERTENSIONAHA.107.095448.

24. Wu VC, Kuo CC, Wang SM, et al. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. J Hypertens. 2011;29(9):1778-86. doi:10.1097/HJH.0b013e3283495cbb.

25. Sechi LA, Colussi G, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens. 2010;23(12):1253-60. doi:10.1038/ajh.2010.169.

26. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66(5):607-18. doi:10.1111/j.1365-2265.2007.02775.x.

27. Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126-48. doi:10.1111/joim.12831.

28. Funder J. Primary aldosteronism. Trends Cardiovasc Med. 2022;32(4):228-33. doi:10.1016/j.tcm.2021.03.005.

29. Aglony M, Martínez-Aguayo A, Carvajal CA, et al. Frequency of familial hyperaldosteronism type 1 in a hypertensive pediatric population: clinical and biochemical presentation. Hypertension. 2011;57(6):1117-21. doi:10.1161/HYPERTENSIONAHA.110.168740.

30. Mulatero P, Tizzani D, Viola A, et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension. 2011;58(5):797-803. doi:10.1161/HYPERTENSIONAHA.111.175083.

31. Rossi GP. An update of the guidelines for diagnosis and management of primary aldosteronism. Hypertension Unit, Dept. of Medicine DIMED — University of Padova, Italy. Scienti!c Newsletter. 2021, 26, nr. 79 https://www.eshonline.org/esh-content/uploads/2021/07/AN-UPDATE-OF-THE-GUIDELINES-FOR-DIAGNOSIS-ANDMANAGEMENT-OF-PRIMARY-ALDOSTERONISM.pdf-.pdf.

32. Naruse M, Katabami T, Shibata H, et al. Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr J. 2022;69(4):327-59. doi:10.1507/endocrj.EJ21-0508.

33. Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens. 2020;38(10):1919-28. doi:10.1097/HJH.0000000000002510.

34. Rabi DM, McBrien KA, Sapir-Pichhadze R, et al. Hypertension Canada’s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Can J Cardiol. 2020;36(5):596-624. doi:10.1016/j.cjca.2020.02.086.

35. Rossi GP, Bisogni V, Bacca AV, et al. The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. Int J Cardiol Hypertens. 2020;5:100029. doi:10.1016/j.ijchy.2020.100029.

36. Stowasser M, Ahmed AH, Pimenta E, et al. Factors affecting the aldosterone/renin ratio. Horm Metab Res. 2012;44(3):170-6. doi:10.1055/s-0031-1295460.

37. Ahmed AH, Gordon RD, Ward G, et al. Effect of Moxonidine on the Aldosterone/Renin Ratio in Healthy Male Volunteers. J Clin Endocrinol Metab. 2017;102(6):2039-43. doi:10.1210/jc.2016-3821.

38. Ahmed AH, Gordon RD, Ward G, et al. Effect of Combined Hormonal Replacement Therapy on the Aldosterone/Renin Ratio in Postmenopausal Women. J Clin Endocrinol Metab. 2017;102(7):2329-34. doi:10.1210/jc.2016-3851.

39. Ahmed AH, Gordon RD, Taylor PJ, et al. Effect of contraceptives on aldosterone/renin ratio may vary according to the components of contraceptive, renin assay method, and possibly route of administration. J Clin Endocrinol Metab. 2011;96(6):1797-804. doi:10.1210/jc.2010-2918.

40. Ahmed AH, Gordon RD, Taylor PJ, et al. Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men? J Clin Endocrinol Metab. 2011;96(2):E340-E346. doi:10.1210/jc.2010-1355.

41. Ng E, Gwini SM, Libianto R, et al. Aldosterone, Renin, and Aldosterone-to-Renin Ratio Variability in Screening for Primary Aldosteronism. J Clin Endocrinol Metab. 2022;108(1):33-41. Erratum in: J Clin Endocrinol Metab. 2023. doi:10.1210/clinem/dgac568.

42. Stowasser M, Gordon RD. Primary aldosteronism–careful investigation is essential and rewarding. Mol Cell Endocrinol. 2004;217(1-2):33-9. doi:10.1016/j.mce.2003.10.006.

43. Gordon RD, Stowasser M, Klemm SA, Tunny TJ. Primary aldosteronism and other forms of mineralocorticoid hypertension. In: Swales JD, ed. Textbook of Hypertension. London, UK: Blackwell Scientific; 1994:865-92.

44. Vaidya A, Carey RM. Evolution of the Primary Aldosteronism Syndrome: Updating the Approach. J Clin Endocrinol Metab. 2020;105(12):3771-3783. Erratum in: J Clin Endocrinol Metab. 2021;106(1):e414. doi:10.1210/clinem/dgaa606.

45. Dedov II, Melnichenko GA, Mokrysheva NG. Project Clinical recommendations Primary hyperaldosteronism. 2021. (In Russ.)

46. Sawka AM, Young WF, Thompson GB, et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med. 2001;135(4):258-61. doi:10.7326/0003-4819-135-4-200108210-00010.

47. Young WF, Stanson AW, Thompson GB, et al. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136(6):1227-35. doi:10.1016/j.surg.2004.06.051.

48. Citton M, Viel G, Rossi GP, et al. Outcome of surgical treatment of primary aldosteronism. Langenbecks Arch Surg. 2015;400(3):325-31. doi:10.1007/s00423-014-1269-4.

49. Wachtel H, Cerullo I, Bartlett EK, et al. Long-term blood pressure control in patients undergoing adrenalectomy for primary hyperaldosteronism. Surgery. 2014;156(6): 1394-discussion1403. doi:10.1016/j.surg.2014.08.021.

50. Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5(9):689-99. doi:10.1016/S2213-8587(17)30135-3.

51. Lim V, Guo Q, Grant CS, et al. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism. J Clin Endocrinol Metab. 2014;99(8):2712-9. doi:10.1210/jc.2013-4146.

52. Young WF Jr, Klee GG. Primary aldosteronism. Diagnostic evaluation. Endocrinol Metab Clin North Am. 1988;17(2):367-95.

53. Kendrick ML, Curlee K, Lloyd R, et al. Aldosterone-secreting adrenocortical carcino-mas are associated with unique operative risks and outcomes. Surgery. 2002;132(6): 1008-12. doi:10.1067/msy.2002.128476.

54. Kloos RT, Gross MD, Francis IR, et al. Incidentally discovered adrenal masses. Endocr Rev. 1995;16(4):460-84. doi:10.1210/edrv-16-4-460.

55. Umakoshi H, Ogasawara T, Takeda Y, et al. Accuracy of adrenal computed tomography in predicting the unilateral subtype in young patients with hypokalaemia and elevation of aldosterone in primary aldosteronism. Clin Endocrinol (Oxf). 2018;88(5):645-51. doi:10.1111/cen.13582.

56. Ladurner R, Sommerey S, Buechner S, et al. Accuracy of adrenal imaging and adrenal venous sampling in diagnosing unilateral primary aldosteronism. Eur J Clin Invest. 2017;47(5):372-7. doi:10.1111/eci.12746.

57. Young WF, Stanson AW. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism? Clin Endocrinol (Oxf). 2009;70(1):14-7. doi:10.1111/j.1365-2265.2008.03450.x.

58. Jakobsson H, Farmaki K, Sakinis A, et al. Adrenal venous sampling: the learning curve of a single interventionalist with 282 consecutive procedures. Diagn Interv Radiol. 2018;24(2):89-93. doi:10.5152/dir.2018.17397.

59. Rossi GP, Auchus RJ, Brown M, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2014;63(1):151-60. doi:10.1161/HYPERTENSIONAHA.113.02097.

60. Webb R, Mathur A, Chang R, et al. What is the best criterion for the interpretation of adrenal vein sample results in patients with primary hyperaldosteronism? Ann Surg Oncol. 2012;19(6):1881-6. doi:10.1245/s10434-011-2121-5.

61. Tagawa M, Ghosn M, Wachtel H, et al. Lateralization index but not contralateral suppression at adrenal vein sampling predicts improvement in blood pressure after adrenalectomy for primary aldosteronism. J Hum Hypertens. 2017;31(7):444-9. doi:10.1038/jhh.2016.92.

62. Jackson RV, Lafferty A, Torpy DJ, Stratakis C. New genetic insights in familial hyperaldosteronism. Ann N Y Acad Sci. 2002;970:77-88. doi:10.1111/j.1749-6632.2002.tb04414.x.

63. Halperin F, Dluhy RG. Glucocorticoid-remediable aldosteronism. Endocrinol Metab Clin North Am. 2011;40(2):333-viii. doi:10.1016/j.ecl.2011.01.012.

64. Stowasser M, Gordon RD. Primary aldosteronism: learning from the study of familial varieties. J Hypertens. 2000;18(9):1165-76. doi:10.1097/00004872-200018090-00002.

65. Gordon RD, Stowasser M, Tunny TJ, et al. Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clin Exp Pharmacol Physiol. 1991;18(5):283-6. doi:10.1111/j.1440-1681.1991.tb01446.x.

66. Sukor N, Mulatero P, Gordon RD, et al. Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. J Hypertens. 2008;26(8):1577-82. doi:10.1097/HJH.0b013e3283028352.

67. Scholl UI, Stölting G, Schewe J, et al. CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat Genet. 2018;50(3):349-54. doi:10.1038/s41588-018-0048-5.

68. Fernandes-Rosa FL, Daniil G, Orozco IJ, et al. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism. Nat Genet. 2018;50(3):355-61. doi:10.1038/s41588-018-0053-8.

69. Geller DS, Zhang J, Wisgerhof MV, et al. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 2008;93(8):3117-23. doi:10.1210/jc.2008-0594.

70. Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331(6018):768-72. doi:10.1126/science.1198785.

71. Dutta RK, Söderkvist P, Gimm O. Genetics of primary hyperaldosteronism. Endocr Relat Cancer. 2016;23(10):R437-R454. doi:10.1530/ERC-16-0055.

72. Scholl UI, Stölting G, Nelson-Williams C, et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife. 2015;4:e06315. doi:10.7554/eLife.06315.

73. Daniil G, Fernandes-Rosa FL, Chemin J, et al. CACNA1H Mutations Are Associated With Different Forms of Primary Aldosteronism. EBioMedicine. 2016;13:225-36. doi:10. 1016/j.ebiom.2016.10.002.

74. Marksteiner R, Schurr P, Berjukow S, et al. Inactivation determinants in segment IIIS6 of Ca(v)3.1. J Physiol. 2001;537(Pt 1):27-34. doi:10.1111/j.1469-7793.2001.0027k.x.

75. Scholl UI, Goh G, Stölting G, et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013;45(9):1050-4. doi:10.1038/ng.2695.

76. Assalia A, Gagner M. Laparoscopic adrenalectomy. Br J Surg. 2004;91(10):1259-74. doi:10.1002/bjs.4738.

77. Steichen O, Zinzindohoué F, Plouin PF, Amar L. Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review. Horm Metab Res. 2012;44(3): 221-7. doi:10.1055/s-0031-1299681.

78. Hannon MJ, Sze WC, Carpenter R, et al. Clinical outcomes following unilateral adrenalectomy in patients with primary aldosteronism. QJM. 2017;110(5):277-81. doi:10.1093/qjmed/hcw194.

79. Benham JL, Eldoma M, Khokhar B, et al. Proportion of Patients With Hypertension Resolution Following Adrenalectomy for Primary Aldosteronism: A Systematic Review and Meta-Analysis. J Clin Hypertens (Greenwich). 2016;18(12):1205-12. doi:10.1111/jch.12916.

80. Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60(10):820-5. doi:10.1016/0002-9149(87)91030-7.